Pedro Rosa-Neto
Overview
Explore the profile of Pedro Rosa-Neto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
338
Citations
9310
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hosseini S, Hajianfar G, Hall B, Servaes S, Rosa-Neto P, Ghafarian P, et al.
Cancer Imaging
. 2025 Mar;
25(1):33.
PMID: 40075547
Purpose: This study aimed to select robust features against lung motion in a phantom study and use them as input to feature selection algorithms and machine learning classifiers in a...
2.
Alpaugh M, Lantero-Rodriguez J, Benedet A, Manseau U, Boutin M, Maiuri M, et al.
J Neurol
. 2025 Mar;
272(3):254.
PMID: 40047995
Tau is a microtubule protein that is known to be hyperphosphorylated and to aggregate in several chronic neurodegenerative disorders. In many cases, in particular in Alzheimer's disease, the degree of...
3.
Yakoub Y, Gonzalez-Ortiz F, Ashton N, Dery C, Strikwerda-Brown C, St-Onge F, et al.
Alzheimers Dement
. 2025 Feb;
21(2):e14537.
PMID: 40008832
Introduction: We assessed the prognostic accuracy of plasma p-tau217 in predicting the progression to mild cognitive impairment (MCI) in cognitively unimpaired (CU) individuals over a mean follow-up of 5.65 years...
4.
Leffa D, Povala G, Bellaver B, Ferrari-Souza J, Ferreira P, Lussier F, et al.
Alzheimers Dement
. 2025 Feb;
21(2):e70003.
PMID: 39998851
Introduction: Epidemiological studies indicate a link between attention-deficit/hyperactivity disorder (ADHD) and elevated risk of dementia. However, the impact of ADHD on cognition and Alzheimer's disease (AD) biomarkers in individuals with...
5.
Milella M, Minuzzi L, Benkelfat C, Soucy J, Kirlow A, Schirrmacher E, et al.
Curr Neuropharmacol
. 2025 Feb;
PMID: 39976038
Introduction: In vitro data from primates provide conflicting evidence about the suitability of the cerebellum as a reference region for quantifying type 5 metabotropic glutamate receptor (mGluR5) binding parameters with...
6.
Bateman R, Li Y, McDade E, Llibre-Guerra J, Clifford D, Atri A, et al.
medRxiv
. 2025 Feb;
PMID: 39974075
Background: Amyloid-plaque removal by monoclonal antibody therapies slows clinical progression in symptomatic Alzheimer's disease; however, the potential for delaying the onset of clinical symptoms in asymptomatic people is unknown. The...
7.
Arslan B, Brum W, Pola I, Therriault J, Rahmouni N, Stevenson J, et al.
Alzheimers Res Ther
. 2025 Feb;
17(1):48.
PMID: 39972340
Background: Impaired kidney function has a potential confounding effect on blood biomarker levels, including biomarkers for Alzheimer's disease (AD). Given the imminent use of certain blood biomarkers in the routine...
8.
Yun J, Shin D, Lee E, Kim J, Ham H, Gu Y, et al.
JAMA Neurol
. 2025 Feb;
PMID: 39960728
Importance: Understanding the characteristics of discordance between plasma biomarkers and positron emission tomography (PET) results in Alzheimer disease (AD) is crucial for accurate interpretation of the findings. Objective: To compare...
9.
Islam T, Hill E, Abrahamson E, Servaes S, Smirnov D, Zeng X, et al.
Nat Med
. 2025 Feb;
31(2):574-588.
PMID: 39930142
Patients with Alzheimer's disease (AD) with little or no quantifiable insoluble brain tau neurofibrillary tangle (NFT) pathology demonstrate stronger clinical benefits of therapies than those with advanced NFTs. The formation...
10.
Liu H, Marsh T, Shi X, Renton A, Bowling K, Ziegemeier E, et al.
Brain
. 2025 Feb;
PMID: 39903689
We present a comprehensive global analysis of genetic variants associated with autosomal-dominant Alzheimer's disease (ADAD). A total of 550 variants in the APP, PSEN1, and PSEN2 genes were identified, of...